186 related articles for article (PubMed ID: 23209702)
1. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk.
Cao Q; Ju X; Li P; Meng X; Shao P; Cai H; Wang M; Zhang Z; Qin C; Yin C
PLoS One; 2012; 7(11):e50302. PubMed ID: 23209702
[TBL] [Abstract][Full Text] [Related]
2. Associations of genetic polymorphisms in pTEN/AKT/mTOR signaling pathway genes with cancer risk: A meta-analysis in Asian population.
Zhang Z; Chen Q; Zhang J; Wang Y; Hu X; Yin S; He M; Guan S; Qin W; Xiao Q; Zhao H; Yao W; Wu H; Wei M
Sci Rep; 2017 Dec; 7(1):17844. PubMed ID: 29259266
[TBL] [Abstract][Full Text] [Related]
3. Functional promoter rs2295080 T>G variant in MTOR gene is associated with risk of colorectal cancer in a Chinese population.
Xu M; Gao Y; Yu T; Wang J; Cheng L; Cheng L; Cheng D; Zhu B
Biomed Pharmacother; 2015 Mar; 70():28-32. PubMed ID: 25776475
[TBL] [Abstract][Full Text] [Related]
4. Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population.
Chen J; Shao P; Cao Q; Li P; Li J; Cai H; Zhu J; Wang M; Zhang Z; Qin C; Yin C
PLoS One; 2012; 7(7):e40817. PubMed ID: 22815832
[TBL] [Abstract][Full Text] [Related]
5. A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population.
Xu M; Tao G; Kang M; Gao Y; Zhu H; Gong W; Wang M; Wu D; Zhang Z; Zhao Q
PLoS One; 2013; 8(3):e60080. PubMed ID: 23555892
[TBL] [Abstract][Full Text] [Related]
6. The associations of hub gene polymorphisms in PI3K/AKT/mTOR pathway and Schistosomiasis Japonica infection and hepatic fibrosis.
Xiao Q; Yu H; Zhu X
Infect Genet Evol; 2020 Nov; 85():104423. PubMed ID: 32554084
[TBL] [Abstract][Full Text] [Related]
7. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk.
Shu X; Lin J; Wood CG; Tannir NM; Wu X
J Natl Cancer Inst; 2013 Mar; 105(6):424-32. PubMed ID: 23378641
[TBL] [Abstract][Full Text] [Related]
8. The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
Li X; Zhang R; Liu Z; Li S; Xu H
Oncotarget; 2017 Mar; 8(12):20252-20265. PubMed ID: 28423632
[TBL] [Abstract][Full Text] [Related]
9. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
[TBL] [Abstract][Full Text] [Related]
10. Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer.
Li Q; Yang J; Yu Q; Wu H; Liu B; Xiong H; Hu G; Zhao J; Yuan X; Liao Z
Clin Cancer Res; 2013 Nov; 19(22):6252-60. PubMed ID: 24077347
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants in the mTOR pathway with renal cancer risk and subtypes in East Indian population.
Malakar S; Chatterjee S; Das M; Pal DK
Urologia; 2024 May; 91(2):270-275. PubMed ID: 38205940
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants in PI3K/Akt/mTOR pathway genes contribute to gastric cancer risk.
Ge Y; Liu H; Qiu X; Ma G; Wang H; Du M; Wang M; Zhao Q; Tao G; Chu H; Zhang Z
Gene; 2018 Sep; 670():130-135. PubMed ID: 29802999
[TBL] [Abstract][Full Text] [Related]
13. Variants in angiogenesis-related genes and the risk of clear cell renal cell carcinoma.
Qin C; Chen J; Li J; Ju X; Zhang S; Cao Q; Han Z; Li P; Shao P; Wang M; Zhang Z; Gu M; Zhang W; Yin C
Mutagenesis; 2014 Nov; 29(6):419-25. PubMed ID: 25239121
[TBL] [Abstract][Full Text] [Related]
14. Effects of the MTOR and AKT1 genes polymorphisms on papillary thyroid cancer development.
Maruei-Milan R; Saravani M; Heidari Z; Asadi-Tarani M; Salimi S
IUBMB Life; 2020 Dec; 72(12):2601-2610. PubMed ID: 33107190
[TBL] [Abstract][Full Text] [Related]
15. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
Huang J; Wang X; Wen G; Ren Y
Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
[TBL] [Abstract][Full Text] [Related]
16. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
[TBL] [Abstract][Full Text] [Related]
17. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
18. Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population.
Qin C; Cao Q; Li P; Ju X; Wang M; Chen J; Wu Y; Meng X; Zhu J; Zhang Z; Lu Q; Yin C
PLoS One; 2012; 7(1):e28829. PubMed ID: 22295057
[TBL] [Abstract][Full Text] [Related]
19. Associations of Genetic Polymorphisms of mTOR rs2295080 T/G and rs1883965 G/A with Susceptibility of Urinary System Cancers.
Min Z; Mi Y; Lv Z; Sun Y; Tang B; Wu H; Zhang Z; Pan H; Zhang Y; Lu C; Zuo L; Zhang L
Dis Markers; 2022; 2022():1720851. PubMed ID: 35082928
[TBL] [Abstract][Full Text] [Related]
20. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
